All In Biotech

Drug Trial Radar · NCT03947385

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

A Phase 1/2 Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

Last checked: Nov 20, 2026Latest source record: Jun 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

336

Planned (sponsor's estimate)

Start

Jun 28, 2019

Primary completion

Jan 29, 2027

Study completion Jun 15, 2027

Sponsor

Lead sponsor
IDEAYA BiosciencesIndustry
Sponsor type
Industry
First posted
May 13, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1/2, multi-center, open-label basket study designed to evaluate the safety and anti-tumor activity of IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations or PRKC fusions, including metastatic uveal melanoma (MUM), cutaneous melanoma, colorectal cancer, and other solid tumors. Phase 1 (dose escalation - monotherapy) will assess safety, tolerability and pharmacokinetics of IDE196 via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - binimetib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and binimetinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Phase 1 (dose escalation - crizotinib combination) will assess safety, tolerability and pharmacokinetics of IDE196 and crizotinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and anti-tumor activity will be assessed in the Phase 2 (dose expansion) part of the study. Evaluation of safety and efficacy across multiple doses may be explored in the dose optimization part of the study. Crizotinib monotherapy with crossover to combination cohort may be assessed for safety and to show the contribution of each study drug to anti-tumor activity. As of Protocol Amendment 10, Phase 1, Phase 2 dose expansion in IDE196 monotherapy, and Phase 2 dose expansion of IDE196 in combination with binimetinib have been fully enrolled. There were no patients enrolled in the crizotinib monotherapy cohorts.

Conditions

  • Metastatic Uveal Melanoma
  • Cutaneous Melanoma
  • Colorectal Cancer
  • Other Solid Tumors

Interventions

  • IDE196Drug

    IDE196 dosed orally, twice daily for each 28-day cycle

  • BinimetinibDrug

    Binimetinib dosed orally, twice daily for each 28-day cycle

  • CrizotinibDrug

    Crizotinib dosed orally, twice daily for each 28-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limiting Toxicity (DLT)Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
  2. Incidence of Adverse EventsTime frame: Approx. 8 months
  3. Maximum Tolerated Dose (MTD)Time frame: 28 days following first dose of IDE196 as monotherapy, in combination with Binimetinib, or in combination with Crizotinib
  4. Recommended Phase 2 Dose (RP2D) as monotherapy, in combination with Binimetinib, or in combination with CrizotinibTime frame: Approx. 6 months
  5. Plasma Concentrations of IDE196 as monotherapy, in combination with Binimetinib, or in combination with CrizotinibTime frame: Approx. 6 months
  6. Plasma Concentrations of Crizotinib administered in combination with IDE196Time frame: Approx. 6 months
  7. Plasma Concentrations of Binimetinib administered in combination with IDE196Time frame: Approx. 6 months
  8. Overall Response Rate (ORR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessmentTime frame: Approx. 8 months
  9. Duration of Response (DOR) of IDE196 monotherapy, in combination with Binimetinib, and in combination with Crizotinib in Dose Expansion cohorts by Investigator response assessmentTime frame: Approx. 8 months

Locations

15 sites in 3 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Los Angeles, California · Recruiting

  • San Francisco Oncology Associates

    San Francisco, California · Active not recruiting

  • SCRI - Denver

    Denver, Colorado · Recruiting

  • University of Iowa

    Iowa City, Iowa · Active not recruiting

  • Cancer Hematology Centers Western Michigan

    Grand Rapids, Michigan · Active not recruiting

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York · Active not recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio · Recruiting

  • The Cleveland Clinic Foundation

    Cleveland, Ohio · Active not recruiting

  • Sidney Kimmel Cancer Center at Thomas Jefferson University

    Philadelphia, Pennsylvania · Recruiting

  • The Sarah Cannon Research Institute/Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Queensland

    Woolloongabba, Australia · Active not recruiting

  • Westmead Hospital

    Sydney, New South Wales, Australia · Active not recruiting

  • Princess Margaret Cancer Centre

    Toronto, Ontario, Canada · Active not recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.